Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA
Switching to faricimab improved anatomy in highly treatment-resistant CNV eyes, indicating its potential when other therapeutic options have failed.
Authors
- Nehal Nailesh Mehta (ORCID: https://orcid.org/0000-0003-4653-2021)
- Alexandra Warter (ORCID: https://orcid.org/0000-0001-6569-8452)
- Anna Heinke (ORCID: https://orcid.org/0000-0002-7115-8767)
- Akshay Agnihotri (ORCID: https://orcid.org/0009-0001-4624-8250)
- Lingyun Cheng (ORCID: https://orcid.org/0000-0002-0748-5173)
- Carlo Miguel B. Galang
- Dirk‐Uwe Bartsch (ORCID: https://orcid.org/0000-0003-0955-8708)
- Daniel N. Deussen
- Henry Ferreyra (ORCID: https://orcid.org/0000-0002-0378-6294)
- William R. Freeman (ORCID: https://orcid.org/0000-0001-9979-2500)
- Ines Doris Nagel (ORCID: https://orcid.org/0000-0002-4649-6764)
Institutions
- University Hospital Augsburg (DE)
- University of California San Diego (US)
- The Retina Center (US)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- International Journal of Retina and Vitreous
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1186/s40942-025-00691-4
- Citations
- 7
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 11.95
Funders
- Research to Prevent Blindness
- National Institutes of Health
- University of California, San Diego